Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Propanc Biopharma, Inc. (PPCB)
USD1.63
+0.00 (+0.00%)
AU NASDAQ Healthcare Biotechnology
Address
302, 6 Butler Street 3124
Camberwell, VIC, AU
Camberwell, VIC, AU
CEO
James Nathanielsz
Website
propanc.com
IPO
2012-11-12
CIK 1517681 ISIN US74346N8002
Also trades on
NASDAQ Capital Market · PPCB (USD)
Other OTC · PPCBD (USD)
Description
Propanc Biopharma, Inc. (PPCB) is an Australian biopharmaceutical firm dedicated to developing innovative treatments for various cancers, with a particular focus on pancreatic, ovarian, and colorectal malignancies. The company's leading therapeutic candidate, PRP, is a unique formulation currently in the preclinical stage of development. This product is designed to enhance the effectiveness of multiple enzymes that work together to combat cancer. Propanc Biopharma is also engaged in a collaborative research effort with the University of Jaén, initiating the POP1 joint drug discovery program. Founded in 2007, the entity was originally known as Propanc Health Group Corporation before officially changing its name to Propanc Biopharma, Inc. in April 2017. The company's headquarters are located in Camberwell, Australia.
News Sentiment (7d)
Based on only 1 article — low confidence
- Propanc Biopharma Signs MOU with Avance Clinical Pty Ltd GlobeNewsWire
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD1.63
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
4M
Beta
3.30
Float Shares
13.65M
Free Float %
90.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -21.40% | -21.40% | -25.03% | -65.68% | -90.60% | -86.38% | -97.39% | -81.73% | -99.97% | -100.00% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
1.63
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-17.41
Distress
Piotroski F-Score
4 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+98.8% ★ Q1'26: +97.8% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-373.6% Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+279,940.7% Q1'26: +418.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.03× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 5/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
7
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Putney Consultants Ltd. | 32.94M | 36.20% | 32.94M | — | 32.94M | 10.00 | CO | 6. Citizenship or Place of Organization | 2015-01-02 | ↗ |
| 2 | Oasis Capital, LLC | 14.03M | 9.99% | 14.03M | — | 14.03M | — | — | United States of America, Territory of Puerto Rico | 2020-07-07 | ↗ |
| 3 | Iwona Aniela Ostrowski | 6.50M | 8.90% | — | 6.50M | — | — | IN | Australia | 2013-08-02 | ↗ |
| 4 | John Ostrowski | 6.50M | 8.90% | — | 6.50M | — | — | IN | Australia | 2013-08-02 | ↗ |
| 5 | Ostrowski Properties Pty Ltd (ACN 087 798 276) | 6.50M | 8.90% | — | 6.50M | — | — | CO | Australia | 2013-08-02 | ↗ |
| 6 | Ross Silver | 3.63M | 9.25% | — | 3.63M | — | 3.63M | IN | Oregon, United States | 2021-09-08 | ↗ |
| 7 | Sylva International LLC | 3.63M | 9.25% | — | 3.63M | — | 3.63M | OO | Oregon, United States | 2021-09-08 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
3.00
Bullish
Buys
3
Sells
1
Shares acquired
12.15M
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+12,148,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-07-05 | ZELINGER JOSEF | Director | A-Award | A | Common Stock Purchase Warrant | 15,000,000 | 0.01 | 150.0K | 15,000,000 | — | ↗ |
| 2021-08-17 | ZELINGER JOSEF | Director | — | D | Common stock, par value $0.001 | 0 | 0.00 | — | 2,800,000 | — | ↗ |
| 2021-08-17 | Nathanielsz James Andrew | Director / Officer | A-Award | A | Common stock, par value $0.001 | 5,928,000 | 0.00 | — | 5,928,004 | — | ↗ |
| 2021-08-17 | Kenyon Julian Norman | Director / Officer | A-Award | A | Common stock, par value $0.001 | 3,420,000 | 0.00 | — | 3,420,005 | — | ↗ |
| 2019-06-24 | Campiciano Carlo M | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-05-14 | Nathanielsz James Andrew | Director / Officer | A-Award | A | Stock Options (Right to Buy) | 19,500,000 | 0.01 | 183.3K | 19,500,000 | — | ↗ |
| 2019-05-14 | Kenyon Julian Norman | Director / Officer | A-Award | A | Stock Options (Right to Buy) | 9,750,000 | 0.01 | 82.9K | 9,750,000 | — | ↗ |
| 2016-04-14 | Nathanielsz James Andrew | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 71,500,000 | 0.03 | 2.15M | 71,500,000 | — | ↗ |
| 2016-04-14 | Kenyon Julian Norman | Director | A-Award | A | Stock Option (Right to Buy) | 71,500,000 | 0.03 | 2.15M | 71,500,000 | — | ↗ |
| 2015-02-04 | Nathanielsz James Andrew | Director / Officer | J-Other | A | Common Stock, par value $0.001 | 33,259,350 | 33,259.00 | 1.11T | 42,711,111 | — | ↗ |
| 2015-02-04 | Kenyon Julian Norman | Director | J-Other | A | Common Stock, par value $0.001 | 17,654,470 | 17,654.00 | 311.67B | 28,466,534 | — | ↗ |
| 2014-11-09 | Nathanielsz James Andrew | Director / Officer / 10% Owner | A-Award | A | Series A Preferred Stock | 500,000 | 0.00 | — | 500,000 | — | ↗ |
| 2013-07-05 | Nathanielsz James Andrew | Director / Officer / 10% Owner | S-Sale | D | Common stock, par value $0.001 per share | 55,000 | 0.09 | 5.0K | 9,701,761 | — | ↗ |
| 2013-01-23 | Nathanielsz James Andrew | Director / Officer / 10% Owner | S-Sale | D | Common stock, par value $0.001 per share | 15,000 | 0.20 | 3.0K | 9,756,761 | — | ↗ |
| 2012-12-13 | Nathanielsz James Andrew | Director / Officer / 10% Owner | S-Sale | D | Common stock, par value $0.001 per share | 5,500 | 0.20 | 1.1K | 9,771,761 | — | ↗ |
| 2012-09-14 | Nathanielsz James Andrew | Director / Officer / 10% Owner | S-Sale | D | Common stock, par value $0.001 per share | 5,000 | 0.20 | 1.0K | 9,777,261 | — | ↗ |
| 2012-09-04 | Nathanielsz James Andrew | Director / Officer / 10% Owner | S-Sale | D | Common stock, par value $0.001 per share | 250,000 | 0.20 | 50.0K | 9,782,261 | — | ↗ |
| 2012-08-23 | Nathanielsz James Andrew | Director / Officer / 10% Owner | P-Purchase | D | Common Stock | 250,000 | 0.20 | 50.0K | 9,782,261 | — | ↗ |
| 2012-07-16 | Kenyon Julian Norman | Director / 10% Owner | — | D | Shares in Propanc Health Group Corp. | 0 | 0.00 | — | 2,703,016 | — | ↗ |
| 2011-12-16 | Nathanielsz James Andrew | Director / Officer / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 10,032,261 | — | ↗ |
Executive team
Top executives
Shares Outstanding
15.17M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
| Filing date | Form type | Filing |
|---|---|---|
| 2026-03-19 | PRE 14A | ↗ |
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| James Nathanielsz | Chief Executive Officer & Executive Chairman | 563.7K | male |
| Klaus Kutz | Chief Medical Officer & Member of Scientific Advisory Board | 18.2K | — |
| Jeannine Zimmerman | Chief Financial Officer | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PPCB
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
